Have the answer right when you need it. Diagnexia and Stratipath have partnered to bring rapid, cost-effective, and clinically validated AI-based prognostic testing to breast cancer diagnostics across the UK and Europe.
Order NowTraditional testing is slow, costly and limited. Current gene expression tests can take 1–2 weeks, cost thousands, and are often inaccessible due to their complexity and cost. This can delay treatment decisions and contribute to health inequities in breast cancer care.
Stratipath Breast utilises a single routine H&E-stained slide to classify a Patients tumor into high- or low-risk categories, providing clear cost effective results and reducing the need for expensive molecular testing.
Now available via Diagnexia’s digital pathology platform, it offers:
Utilise your digital Pathology images or let us collect and scan your slides, Diagnexia is there to make sure you have the results ready for MDT.
By removing barriers to prognostic testing, this partnership helps democratize access to personalised cancer care:
Whether you're a histopathologist looking to streamline workflows or an oncologist in need of timely prognostic insights, this solution fits seamlessly into your clinical environment—no new infrastructure required.
A global leader in AI-powered digital pathology, offering expert diagnostic services and scalable digital workflows.
An AI-driven oncology company delivering cutting-edge precision diagnostics through CE-marked and UK-validated software tools.
Find out how Diagnexia with Stratipath can help your lab, hospital or oncology team.